# Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

> **NCT05783622** · PHASE1 · RECRUITING · sponsor: **Janux Therapeutics** · enrollment: 130 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Renal Cell Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Colorectal Carcinoma
- Small Cell Lung Cancer
- Pancreatic Ductal Adenocarcinoma
- Triple-negative Breast Cancer

## Interventions

- **DRUG:** JANX008

## Key facts

- **NCT ID:** NCT05783622
- **Lead sponsor:** Janux Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2026-01
- **Final completion:** 2027-10
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05783622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05783622, "Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05783622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*